{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-037923","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.305328+00:00","generated_at":"2026-05-17T20:23:59.380042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%","bullets":["Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).","Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.","Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.","Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.","Cash and equivalents $16M; total assets $68M; shareholders' equity $28M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-037923","json":"https://secwatch.observer/filing/0001628280-25-037923.json","markdown":"https://secwatch.observer/filing/0001628280-25-037923.md","text":"https://secwatch.observer/filing/0001628280-25-037923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/0001628280-25-037923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/cpix-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:23:59.380042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}